Coronavirus Update: Pfizer Switches To Alternate COVID Vaccine Over T Cell Response

Plus: Yuhan and Abclon Advance Candidate

28 Jul 2020

• By Scrip Team

Signs that BNT162b2 could be more effective in older age groups led companies to switch lead candidates, and they now head into a pivotal late-stage study.

Pfizer Inc. and BioNTech SE have switched to their ‘backup’ COVID-19 vaccine candidate after finding that it could provide a greater T cell immune response in older in patients and greater tolerability.

The companies will now take their BNT162b2 vaccine candidate into the Phase II/III study, rather than BNT162b1, its closely related variant which

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

09 May 2025

• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.